|
|
Long term survivors with
glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and
nitrosurea have higher initial expression of Ki-67
A. K. Choucair, W. Seiferheld, C. Ford, J. Hansen, B. Dabbas, C. Schultz, A.
Schulsinger, M. Mehta, W. Curran
LDS Hospital, Salt Lake City, UT; American College of Radiology,
RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; Suny Health
Science Center, Brooklyn, NY; University of Wisconsin, Madison, WI; Thomas
Jefferson University Hospital, Philadelphia, PA
Background. Ki-67 is a nuclear antigen that is upregulated during
cellular proliferation.
Ki-67 expression has been both positively and negatively associated with
survival in a number of tumor primaries.
Similarly, in patients with GBM, prior studies of the prognostic value of
initial Ki-67 expression for overall survival have reported conflicting results
with some suggesting a positive, others a negative, and others no
correlation.
Methods. In this study we compared the nuclear expression of Ki-67 using
Mib-1 antibody between 28 long term (>18 months) and 35 short term (< 6
months) GBM survivors receiving irradiation and BCNU who were selected from RTOG
Tissue Bank and who met the following criteria: eligibility requirements for the
RTOG study on which they were enrolled, received the BCNU arm, and had survival
18 months.
Tumor cell expression was quantitated by performing immunohistochemistry on
tumor array slides with determination of positively staining cells by use of the
Chromovision automated cell imaging system.
Results.
|
|
|
Min.
|
Max.
|
Mean
|
p(univariate)
|
*p(multivariate)
|
|
Short term survivors
|
0
|
29
|
6.1
|
0.007
|
0.016
|
|
Long term survivors
|
1
|
58
|
15.5
|
Conclusions.
In this patient population, long term GBM survivors have a
higher percentage of tumor cells expressing Ki-67.
This suggests that further investigation of factors that are altered during the
cell cycle may be of value in identifying prognostic factors for long term GBM
survivors.
Copyright 2004 American Society of Clinical Oncology All rights
reserved worldwide.
Source: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-001686,00.asp
|
